These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 28802755)

  • 1. Pneumococcal conjugate vaccination response in patients after community-acquired pneumonia, differences in patients with S. pneumoniae versus other pathogens.
    Wagenvoort GHJ; Vlaminckx BJM; van Kessel DA; Geever RCL; de Jong BAW; Grutters JC; Bos WJW; Meek B; Rijkers GT
    Vaccine; 2017 Sep; 35(37):4886-4895. PubMed ID: 28802755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay.
    Pletz MW; Ewig S; Rohde G; Schuette H; Rupp J; Welte T; Suttorp N; Forstner C;
    Vaccine; 2016 Apr; 34(20):2342-8. PubMed ID: 27016653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
    Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
    Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
    LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk W; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
    Vaccine; 2019 Aug; 37(36):5466-5473. PubMed ID: 31345638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
    Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS
    PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.
    Sherwin RL; Gray S; Alexander R; McGovern PC; Graepel J; Pride MW; Purdy J; Paradiso P; File TM
    J Infect Dis; 2013 Dec; 208(11):1813-20. PubMed ID: 24092845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children.
    Esposito S; Principi N;
    Future Microbiol; 2015; 10(10):1599-607. PubMed ID: 26439470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.
    Rodrigo C; Bewick T; Sheppard C; Greenwood S; Mckeever TM; Trotter CL; Slack M; George R; Lim WS
    Eur Respir J; 2015 Jun; 45(6):1632-41. PubMed ID: 25792633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia.
    Sings HL
    Vaccine; 2017 Sep; 35(40):5406-5417. PubMed ID: 28602602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 13-Valent vaccine serotype pneumococcal community acquired pneumonia in adults in high clinical risk groups.
    Daniel P; Rodrigo C; Bewick T; Sheppard C; Greenwood S; McKeever TM; Trotter C; Lim WS
    Vaccine; 2018 Mar; 36(12):1614-1620. PubMed ID: 29439865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.
    McLaughlin JM; Jiang Q; Isturiz RE; Sings HL; Swerdlow DL; Gessner BD; Carrico RM; Peyrani P; Wiemken TL; Mattingly WA; Ramirez JA; Jodar L
    Clin Infect Dis; 2018 Oct; 67(10):1498-1506. PubMed ID: 29790925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study.
    Menéndez R; España PP; Pérez-Trallero E; Uranga A; Méndez R; Cilloniz C; Marimón JM; Cifuentes I; Méndez C; Torres A
    Vaccine; 2017 Sep; 35(39):5264-5270. PubMed ID: 28823622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia.
    Forstner C; Kolditz M; Kesselmeier M; Ewig S; Rohde G; Barten-Neiner G; Rupp J; Witzenrath M; Welte T; Pletz MW;
    Vaccine; 2020 Jan; 38(5):1129-1136. PubMed ID: 31761500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential role of 13-valent pneumococcal conjugate vaccine in preventing respiratory complications in bacteraemic pneumococcal community-acquired pneumonia.
    Sanz-Herrero F; Gimeno-Cardona C; Tormo-Palop N; Fernández-Fabrellas E; Briones ML; Cervera-Juan Á; Blanquer-Olivas J
    Vaccine; 2016 Apr; 34(15):1847-52. PubMed ID: 26845737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
    Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
    Vaccine; 2019 May; 37(20):2687-2693. PubMed ID: 30975569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease.
    Principi N; Esposito S
    Expert Rev Vaccines; 2015; 14(10):1359-66. PubMed ID: 26289973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children.
    Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
    Vaccine; 2017 Feb; 35(6):945-950. PubMed ID: 28087146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010-2015.
    Silva-Costa C; Brito MJ; Pinho MD; Friães A; Aguiar SI; Ramirez M; Melo-Cristino J; ;
    Emerg Infect Dis; 2018 Jul; 24(7):1307-1314. PubMed ID: 29912700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.